CN114478672A - Synthetic method of HE3286 - Google Patents
Synthetic method of HE3286 Download PDFInfo
- Publication number
- CN114478672A CN114478672A CN202210119479.5A CN202210119479A CN114478672A CN 114478672 A CN114478672 A CN 114478672A CN 202210119479 A CN202210119479 A CN 202210119479A CN 114478672 A CN114478672 A CN 114478672A
- Authority
- CN
- China
- Prior art keywords
- solvent
- compound
- reaction
- weight ratio
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010189 synthetic method Methods 0.000 title abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 50
- 238000005984 hydrogenation reaction Methods 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 9
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 8
- 238000005886 esterification reaction Methods 0.000 claims abstract description 7
- 230000017105 transposition Effects 0.000 claims abstract description 7
- 238000003379 elimination reaction Methods 0.000 claims abstract description 6
- 238000005905 alkynylation reaction Methods 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 74
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 69
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 60
- 239000002904 solvent Substances 0.000 claims description 51
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000003513 alkali Substances 0.000 claims description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000012074 organic phase Substances 0.000 claims description 14
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 14
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 14
- 238000004537 pulping Methods 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001308 synthesis method Methods 0.000 claims description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 claims description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 7
- 235000011056 potassium acetate Nutrition 0.000 claims description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- 238000001953 recrystallisation Methods 0.000 claims description 7
- 230000002194 synthesizing effect Effects 0.000 claims description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- -1 ethynyl Grignard reagent Chemical class 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- LROBJRRFCPYLIT-UHFFFAOYSA-M magnesium;ethyne;bromide Chemical group [Mg+2].[Br-].[C-]#C LROBJRRFCPYLIT-UHFFFAOYSA-M 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 238000010791 quenching Methods 0.000 claims description 6
- 239000012266 salt solution Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 5
- 238000006722 reduction reaction Methods 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 4
- 239000007818 Grignard reagent Substances 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 150000003863 ammonium salts Chemical class 0.000 claims description 4
- 238000010009 beating Methods 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 230000000171 quenching effect Effects 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 239000012043 crude product Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- HUGJUYPSXULVQQ-UHFFFAOYSA-M Br[Mg]C#C Chemical compound Br[Mg]C#C HUGJUYPSXULVQQ-UHFFFAOYSA-M 0.000 claims description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 235000019270 ammonium chloride Nutrition 0.000 claims description 2
- 239000012065 filter cake Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000002585 base Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 5
- 239000010410 layer Substances 0.000 description 20
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 4
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- NCMZQTLCXHGLOK-ZKHIMWLXSA-N prasterone acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 NCMZQTLCXHGLOK-ZKHIMWLXSA-N 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 229930194542 Keto Natural products 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 2
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 2
- 229960004845 drospirenone Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
- C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0048—Alkynyl derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
A synthetic method of HE3286 is characterized in that trihydroxy substances (I) are used as raw materials, HE3286 is obtained through the following steps of transposition reaction, double esterification reaction, elimination reaction, hydrogenation reaction, alkynylation reaction and hydrolysis reaction, and the HE3286 is obtained.
Description
Technical Field
The invention relates to a preparation method of an androstane compound.
Background
HE3286, chemically named 17 alpha-ethynylandrost-5-ene-3 beta, 7 beta, 17 beta-triol, is used for preventing or treating metabolic diseases such as type 2 diabetes, hyperglycemia and the like and autoimmune diseases such as rheumatoid arthritis and the like.
So far, WO2009149392 reports 3 synthetic routes to HE 3286.
In the first synthetic route, DHEA is used as an initial raw material, 3-position hydroxyl is protected by TMSCl, then 2 is obtained by adding acetylene to 17-position keto, 7-position keto compound 4 is obtained by oxidation after 3-position acetyl protection, 7-position beta hydroxyl 5 is obtained by reducing compound 4, and finally 3-position hydrolysis is carried out to obtain a target product HE 3286. After 6 steps of reaction, the target product HE3286 is obtained with the total yield of 15%.
In the second synthetic route, rearrangement (DHEA acetate) is used as a starting material, a compound 6 is obtained through ethylene glycol protection, a compound 7 is obtained through 7-site oxidation, a compound 8 is obtained through reduction, then ethylene glycol protection, 3-site ester hydrolysis and 3, 7-site hydroxyl TMS protection are carried out, a compound 11 is obtained, 17-site alkynyl is carried out, and finally TMS deprotection is carried out to obtain a target product HE 3286. After 8 steps of reaction, the target product HE3286 is obtained with the total yield of 6%.
The third synthesis route still uses rearrangement (DHEA acetate) as the starting material, and the compound 13 is obtained by oxidation, the compound 14 is obtained by hydroxylamine amination at the 17-position, and then the 7-position is reduced and the 17-position is hydrolyzed to obtain the intermediate 9, and the intermediate 9 is used for reaching the target product HE3286, which is consistent with the second synthesis route. After 8 steps of reaction, the target product HE3286 is obtained with the total yield of 30%.
Compared with the first and the second synthetic routes, although the yield of the third synthetic route is improved to 30% from the previous 15%, the problems of long route, complex operation and the like still exist
Based on the problems in the prior art, a new synthesis method of HE3286 is provided by combining the existing steroid intermediate product line of the applicant, so that the reaction steps are shortened, and the total reaction yield is further improved, which is a problem to be solved in the prior art.
Disclosure of Invention
In order to solve the problems in the prior art, a novel synthesis method of HE3286 is provided. The method takes drospirenone intermediate trihydroxy compound (I) (CAS: 2963-69-1; 3 beta, 7 alpha, 15 alpha-trihydroxyandrost-5-ene-17-one) in the existing product line of the applicant as a starting material, and reduces the past 8 steps of reaction to 6 steps through transposition, double esterification, elimination, hydrogenation, alkynization and hydrolysis, thereby greatly improving the reaction yield by 80 percent compared with the past reported synthetic route. Since the cost of the trihydroxy compound (I) is lower than that of DHEA and DHEA acetate, the process cost of the invention is greatly reduced compared with the reported process.
The technical scheme provided by the invention is as follows:
a process for synthesizing HE3286 from trihydroxy substance (I) includes transposition reaction, double esterification, elimination reaction, hydrogenation reaction, acetylization reaction and hydrolysis reaction
The synthesis method specifically comprises the following steps:
1) transposition reaction
Dissolving trihydroxy substance (I) in solvent, adding strong acid, heating at room temperature for reflux reaction, adding alkali for neutralization after reaction, extracting with organic solvent, washing the organic phase with saturated salt water, layering, drying, and concentrating to obtain compound (II).
As a preferred technical scheme, the solvent is selected from acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, dioxane, DMF, DMSO, methanol, ethanol, diethyl ether, isopropyl ether, methyl tert-butyl ether, preferably acetone; the volume weight ratio of the acetone to the trihydroxy substances is preferably 6-15: 1; the strong acid is selected from perchloric acid, hydrochloric acid, sulfuric acid or nitric acid, and the weight ratio of the strong acid to the trihydroxy substance (I) is 0.01-1; the strong acid is preferably perchloric acid; the weight ratio of perchloric acid to trihydroxy compounds is 0.04-0.06: 1, and the reaction temperature is 15-40 ℃. The extraction solvent is preferably ethyl acetate.
2) Double esterification reaction
Dissolving the compound (II) in an organic solvent, adding an acid-binding agent, adding pivaloyl chloride at the temperature of 0-50 ℃, reacting, adding an alkali solution for neutralization, washing an organic phase with water and saturated salt water respectively, layering, drying and concentrating the organic phase to obtain a compound (III).
As a preferred technical scheme, the solvent is dichloromethane or chloroform, preferably dichloromethane; the acid-binding agent is selected from pyridine, triethylamine, 4-Dimethylaminopyridine (DMAP) and Diisopropylethylamine (DIPEA), and the weight ratio of the acid-binding agent to the compound (II) is 0.1-10; the acid binding agent is preferably pyridine, the molar ratio of the pivaloyl chloride to the compound (II) is preferably 2.5-3.5: 1, and the molar ratio of the pyridine to the pivaloyl chloride is 1.2-1.5: 1; the reaction temperature is 15-40 ℃.
3) Hogwash removal reaction
Dissolving the compound (III) in a solvent, reacting with alkali at the temperature of 20-70 ℃, quenching, extracting a water layer, combining organic phases, washing with saturated salt water, layering, drying, concentrating the organic phase to obtain a crude compound (IV), adding a pulping solvent for pulping, and filtering to obtain the refined compound (IV).
As a preferred technical scheme, the solvent is selected from one or more of tetrahydrofuran, dioxane, DMF, DMSO, methanol, ethanol, diethyl ether, isopropyl ether, and methyl tert-butyl ether, preferably one of tetrahydrofuran, dioxane, diethyl ether, isopropyl ether, and methyl tert-butyl ether, and more preferably tetrahydrofuran; the alkali is selected from potassium acetate, sodium carbonate, sodium hydroxide or potassium hydroxide, the weight ratio of the alkali to the compound (III) is 0.1-10, preferably 0.2-0.8, the alkali is preferably potassium acetate, the weight ratio of the potassium acetate to the compound (III) is preferably 0.4-0.6, the reaction temperature is 55-65 ℃, a saturated ammonium chloride solution is adopted for quenching, and ethyl acetate is used as an extraction solvent; the pulping solvent is a mixed solvent of petroleum ether and ethyl acetate, the ratio is 1-20: 1, preferably 14-18: 1, and the volume-weight ratio of the pulping solvent to the compound (III) is 2.5-3.5: 1.
4) Hydrogenation reaction
Dissolving the compound (IV) in a solvent, adding a palladium-carbon catalyst (Pd/C) at 0-50 ℃ for hydrogenation reduction, filtering after the reaction is finished, washing a filter cake by the solvent, and concentrating to obtain a compound (V).
Preferably, the solvent for the hydrogenation reduction reaction is one or a mixture of two solvents such as methanol, ethanol, ethyl acetate, tetrahydrofuran, and the like, more preferably methanol, and the solvent for washing is ethyl acetate. The weight ratio of the palladium-carbon catalyst to the compound (IV) is 0.03-0.07, and H2The pressure is maintained at 10-20 Psi, the reaction temperature is preferably 15-30 ℃, and the volume-to-weight ratio of the methanol to the compound (IV) is 8-11: 1.
5) Alkynylation reaction
Dissolving the compound (V) in an organic solvent, adding an ethynyl Grignard reagent under the protection of nitrogen, and reacting at-10 ℃ to complete under reflux. Adding ammonium salt solution to quench reaction, adding water to separate layers, extracting water layer with organic solvent, mixing organic phases, separating layers, washing with water, separating layers again, washing with saturated salt solution, separating layers, drying, concentrating organic phase, adding pulping solvent into product, pulping, filtering, and drying to obtain compound (VI).
As a preferred technical scheme, the solvent is selected from tetrahydrofuran, diethyl ether, isopropyl ether, methyl tert-butyl ether and ethylene glycol dimethyl ether, and is preferably tetrahydrofuran. The ethynyl grignard reagent is preferably ethynyl magnesium bromide, and the molar ratio of the ethynyl magnesium bromide to the compound (V) is 1.05 to 5, more preferably 1.05 to 1.2; the temperature of the reaction system is controlled to be-10-0 ℃ when the acetenyl magnesium bromide is dripped, and the reaction temperature is controlled to be 30-40 ℃ after dripping. The ammonium salt solution is an ammonium chloride aqueous solution, the extracted organic solvent is preferably ethyl acetate, the beating solvent is acetonitrile, and the volume-weight ratio of the beating solvent to the compound V is 1-2.
6) Hydrolysis reaction
Dissolving the compound (VI) in a solvent, adding alkali, heating at room temperature to reflux and react completely, adding the reaction solution into water at room temperature, separating out solids, filtering to obtain a target product HE3286 crude product, and recrystallizing to obtain the target product HE 3286.
As a preferred technical solution, the solvent is selected from methanol, ethanol or tetrahydrofuran, preferably methanol; the volume-weight ratio of the methanol to the compound (VI) is 8-12: 1; the alkali is selected from sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate or potassium carbonate, and the weight ratio of the alkali to the compound (VI) is 0.1-10, more preferably 0.2-1; the alkali is preferably potassium hydroxide, the weight ratio of the potassium hydroxide to the compound (VI) is 2.5-3: 1, and the reaction temperature is preferably 45-55 ℃.
The recrystallization solvent is methanol with the water content of 7-10% by volume percentage. The recrystallization method comprises the steps of completely dissolving the HE3286 crude product in a recrystallization solvent, evaporating partial methanol until solid begins to be separated out, cooling to-10-5 ℃ for crystallization, filtering and drying to obtain the target product HE 3286.
The HE3286 synthesis method provided by the invention selects different raw materials and synthesis routes, takes an important intermediate compound (I) produced by drospirenone as an initial raw material, and obtains the target product HE3286 through transposition, double esterification, elimination, hydrogenation, alkynylation and hydrolysis, thereby greatly improving the total yield of the reaction to about 80% on the basis of the prior art. The trihydroxy compound (I) is an intermediate compound which is efficiently converted from DHEA by the applicant in a biological fermentation method and is produced on a large scale. By adopting the synthesis method provided by the invention, the HE3286 is produced by taking the trihydroxy substances as the raw materials through reasonably designing a route and selecting proper reaction conditions, so that the yield of the HE3286 can be greatly improved, the production cost is reduced, and the production efficiency is improved.
Detailed Description
The present invention is further illustrated by the following examples, which should not be construed as limiting the scope of the invention.
Example 1
Triolate (I) (1.0kg, HPLC content 99.1%) was dissolved in acetone (10L), and perchloric acid (50g) was added to the solution to react at room temperature for 2 hours. TLC detection reaction was complete, saturated sodium bicarbonate was neutralized, water (2L) was added, ethyl acetate (5L) was extracted, the layers were separated, saturated brine was washed (2L), the layers were separated, dried over anhydrous sodium sulfate, and concentrated to give compound (II) (991.0g) as a pale yellow solid with a molar yield of 99.1%.
Example 2
Dissolving compound (II) (750.0g) in dichloromethane (7.5L), adding pyridine (370.0g), stirring at room temperature, adding pivaloyl chloride (423.3g) in portions, stirring at room temperature, reacting, adding saturated sodium bicarbonate solution to neutralize, separating layers, washing dichloromethane layer with water (1.5L), separating layers, washing with saturated saline (1.5L), separating layers, drying with anhydrous sodium sulfate, concentrating to obtain compound (V) (1.14kg) with molar yield of 99.5%
Example 3
Compound (III) (500.0g) was dissolved in THF (2500mL), and potassium acetate (251g) was added thereto, followed by heating and refluxing for 16 hours. The reaction was completed by TLC detection and stopped. Cooling to normal temperature, adding saturated NH4Cl solution (500mL), layers were separated, the aqueous layer was extracted with ethyl acetate (300mL), layers were separated, the organic layers were combined, washed with saturated brine (500mL), layers were separated, concentrated, and dried to give crude compound (IV) as a pale yellow solid (480.0 g). Petroleum Ether (PE)/Ethyl Acetate (EA) ═ 15/1(1600mL, v/v) was slurried to give compound (IV) (381.0g) as a white solid in 96.4 mole yield.
Example 4
Compound (IV) (230g) was dissolved in methanol (2300mL), and 5% Pd/C (11.5g), H was added2(15Psi), reaction at 25 ℃ for 2 hours, TLC check of reaction completion, suction filtration, cake washing with Ethyl Acetate (EA) twice, 300mL each, drying to give compound (V) (229.0g) as a white solid in 99% molar yield.
Example 5
Compound (V) (180.0g) was dissolved in a THF (1L) solution, and ethynylmagnesium bromide (1.95L, 0.5M in THF) was added dropwise at 0 ℃ and stirred at room temperature for 1 hour. The temperature is raised to 35 ℃ for reaction for 3 hours. The reaction was completed by TLC detection and stopped. Cooling to normal temperature, and dropwise adding saturated NH4The reaction was quenched with Cl solution (200mL), water (500mL) was added, the layers were separated, the aqueous layer was extracted with ethyl acetate (500mL), the layers were separated, the organic layers were combined, washed with saturated brine (500mL), the layers were separated, dried, and concentrated to give crude compound (VI) as a pale yellow solid (190.0 g). Slurried with (300mL) acetonitrile, filtered and dried to give compound (VI) (175.0g) as a white solid in 91% molar yield.
Example 6
Compound 19(150.0g) was dissolved in a methanol (1.5L) solution, KOH (40.5g) was added, and the mixture was heated to 50 ℃ and stirred for 16 hours. The reaction was completed by TLC detection and stopped. And (3) cooling to normal temperature, dropwise adding the reaction solution into (7.5L) water, carrying out suction filtration, and drying to obtain a compound HE3286(115.0g) as a beige solid. Recrystallization, adding 115 g of compound 4 into methanol/water (10/1 (v/v, 2000mL), heating and refluxing until the mixture is completely dissolved, evaporating partial methanol until solid is precipitated, cooling to 0 ℃ for crystallization, performing suction filtration, and drying to obtain the target compound HE3286(110.2g, HPLC content 99.2%) as a white solid, wherein the molar yield is 92%.
Claims (12)
1. A process for synthesizing HE3286 from trihydroxy substance (I) includes transposition reaction, double esterification, elimination reaction, hydrogenation reaction, acetylization reaction and hydrolysis reaction
The synthesis method specifically comprises the following steps:
1) transposition reaction
Dissolving trihydroxy substance (I) in solvent, adding strong acid, heating at room temperature for reflux reaction, adding alkali for neutralization after reaction, extracting with organic solvent, washing the organic phase with saturated salt water, layering, drying, and concentrating to obtain compound (II);
2) double esterification reaction
Dissolving the compound (II) in an organic solvent, adding an acid-binding agent, adding pivaloyl chloride at the temperature of 0-50 ℃, reacting, adding an alkali solution for neutralization, washing an organic phase with water and saturated salt water respectively, layering, drying and concentrating the organic phase to obtain a compound (III);
3) elimination reaction
Dissolving the compound (III) in a solvent, reacting with alkali at the temperature of 20-70 ℃, quenching, extracting a water layer, combining organic phases, washing with saturated salt water, layering, drying, concentrating the organic phase to obtain a crude compound (IV), adding a pulping solvent for pulping, and filtering to obtain a refined compound (IV);
4) hydrogenation reaction
Dissolving the compound (IV) in a solvent, adding a palladium-carbon catalyst (Pd/C) at 0-50 ℃ for hydrogenation reduction, filtering after the reaction is finished, washing a filter cake by the solvent, and concentrating to obtain a compound (V).
5) Alkynylation reaction
Dissolving the compound (V) in an organic solvent, adding an ethynyl Grignard reagent under the protection of nitrogen, and reacting at-10 ℃ to complete under reflux. Adding ammonium salt solution to quench reaction, adding water to separate layers, extracting water layer with organic solvent, mixing organic phases, separating layers, washing with water, separating layers again, washing with saturated salt solution, separating layers, drying, concentrating organic phase, adding pulping solvent into product, pulping, filtering, and drying to obtain compound (VI);
6) hydrolysis reaction
Dissolving the compound (VI) in a solvent, adding alkali, heating at room temperature to reflux and react completely, adding the reaction solution into water at room temperature, separating out solids, filtering to obtain a target product HE3286 crude product, and recrystallizing to obtain the target product HE 3286.
2. The method for synthesizing HE3286 according to claim 1, wherein in step 1), the solvent is selected from acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, dioxane, DMF, DMSO, methanol, ethanol, diethyl ether, isopropyl ether, methyl tert-butyl ether; (ii) a The strong acid is selected from perchloric acid, hydrochloric acid, sulfuric acid or nitric acid, and the weight ratio of the strong acid to the trihydroxy substance (I) is 0.01-1.
3. The synthesis method of HE3286, according to claim 2, wherein in step 1), the solvent is preferably acetone, and the volume weight ratio of acetone to the trihydroxy compound is preferably 6-15: 1; the strong acid is preferably perchloric acid; the weight ratio of perchloric acid to trihydroxy compounds is 0.04-0.06: 1, and the reaction temperature is 15-40 ℃. The extraction solvent is preferably ethyl acetate.
4. A method of synthesizing HE3286 according to claim 1, wherein in step 2), the solvent is dichloromethane or chloroform; the acid-binding agent is selected from pyridine, triethylamine, 4-Dimethylaminopyridine (DMAP) and Diisopropylethylamine (DIPEA), and the weight ratio of the acid-binding agent to the compound (II) is 0.1-10.
5. The synthesis method of HE3286, according to claim 4, wherein in the step 2), the solvent is preferably dichloromethane, the acid-binding agent is preferably pyridine, the molar ratio of pivaloyl chloride to the compound (II) is preferably 2.5-3.5: 1, the molar ratio of pyridine to pivaloyl chloride is 1.2-1.5: 1, and the reaction temperature is 15-40 ℃.
6. The method for synthesizing HE3286 according to claim 1, wherein in step 3), the solvent is one or more selected from tetrahydrofuran, dioxane, DMF, DMSO, methanol, ethanol, diethyl ether, isopropyl ether and methyl tert-butyl ether; the alkali is selected from potassium acetate, sodium carbonate, sodium hydroxide or potassium hydroxide, the weight ratio of the alkali to the compound (III) is 0.1-10, the pulping solvent is a mixed solvent of petroleum ether and ethyl acetate with the volume ratio of 1-20: 1, the reaction temperature is 55-65 ℃, saturated ammonium chloride solution is adopted for quenching, and ethyl acetate is taken as an extraction solvent.
7. The synthesis method of HE3286, according to claim 1, wherein in step 3), the solvent is preferably one of tetrahydrofuran, dioxane, diethyl ether, isopropyl ether and methyl tert-butyl ether, the base is preferably potassium acetate, and the weight ratio of potassium acetate to compound (III) is preferably 0.4-0.6; the pulping solvent is a mixed solvent of petroleum ether and ethyl acetate in a volume ratio of 14-18: 1, and the volume weight ratio of the pulping solvent to the compound (III) is 2.5-3.5: 1.
8. The synthesis method of HE3286 according to claim 6, wherein in step 4), the solvent for the hydrogenation reduction reaction is one or two of methanol, ethanol, ethyl acetate, tetrahydrofuran, etcMixing the agents, wherein the solvent for cleaning is ethyl acetate. The weight ratio of the palladium-carbon catalyst to the compound (IV) is 0.03-0.07, and H2The pressure is maintained at 10-20 Psi, the reaction temperature is preferably 15-30 ℃, and the volume-to-weight ratio of the methanol to the compound (IV) is 8-11: 1.
9. The method for synthesizing HE3286 according to claim 1, wherein in step 5), the solvent is selected from tetrahydrofuran, diethyl ether, isopropyl ether, methyl tert-butyl ether and ethylene glycol dimethyl ether, the ethynyl grignard reagent is preferably ethynyl magnesium bromide, and the molar ratio of the ethynyl magnesium bromide to the compound (V) is 1.05-5; the temperature of the reaction system is controlled to be-10-0 ℃ when the acetenyl magnesium bromide is dripped, and the reaction temperature is controlled to be 30-40 ℃ after dripping.
10. The method for synthesizing HE3286 according to claim 9, wherein the solvent in step 5) is tetrahydrofuran, the molar ratio of the ethynyl magnesium bromide to the compound (V) is 1.05 to 1.2, the ammonium salt solution is an aqueous ammonium chloride solution, the extracted organic solvent is ethyl acetate, the beating solvent is acetonitrile, and the volume/weight ratio of the beating solvent to the compound V is 1 to 2.
11. The synthesis method of HE3286 according to claim 1, wherein in step 6), the solvent is selected from methanol, ethanol or tetrahydrofuran, the base is selected from sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate or potassium carbonate, the weight ratio of the base to the compound (VI) is 0.1-10, the reaction temperature is preferably 45-55 ℃, the recrystallization solvent is methanol with a water content of 7-10% by volume, the recrystallization method is that the crude HE3286 product is completely dissolved in the recrystallization solvent, part of the methanol is evaporated to precipitate solids, and the target product HE3286 is obtained by cooling, crystallization, filtration and drying.
12. A synthesis process for HE3286 according to claim 11, wherein in step 6), the solvent is preferably methanol; the volume-weight ratio of the methanol to the compound (VI) is 8-12: 1; the alkali is selected from sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate or potassium carbonate, and the weight ratio of the alkali to the compound (VI) is 0.1-10, more preferably 0.2-1; the alkali is preferably potassium hydroxide, and the weight ratio of the potassium hydroxide to the compound (VI) is 2.5-3: 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210119479.5A CN114478672B (en) | 2022-01-27 | 2022-01-27 | Synthesis method of HE3286 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210119479.5A CN114478672B (en) | 2022-01-27 | 2022-01-27 | Synthesis method of HE3286 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114478672A true CN114478672A (en) | 2022-05-13 |
CN114478672B CN114478672B (en) | 2024-06-14 |
Family
ID=81479570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210119479.5A Active CN114478672B (en) | 2022-01-27 | 2022-01-27 | Synthesis method of HE3286 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114478672B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4435327A (en) * | 1981-09-21 | 1984-03-06 | Schering, Aktiengesellschaft | 3β,7β,15α-Trihydroxy-5-androsten-17-one, its 3,15-dipivalate, and their preparation |
CN1694897A (en) * | 2002-11-06 | 2005-11-09 | 法玛西亚普强责任有限公司 | Processes for preparing 7-carboxy substituted steroids |
CN1694894A (en) * | 2001-11-14 | 2005-11-09 | 森托科尔公司 | Anti-IL-6 antibodies, compositions, methods and uses |
WO2009149392A1 (en) * | 2008-06-06 | 2009-12-10 | Hollis-Eden Pharmaceuticals, Inc. | Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds |
CN105246486A (en) * | 2013-03-13 | 2016-01-13 | 萨奇治疗股份有限公司 | Neuroactive steroids and methods of use thereof |
CN111410678A (en) * | 2019-01-08 | 2020-07-14 | 成都康弘药业集团股份有限公司 | Steroid compound, use and preparation method thereof |
-
2022
- 2022-01-27 CN CN202210119479.5A patent/CN114478672B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4435327A (en) * | 1981-09-21 | 1984-03-06 | Schering, Aktiengesellschaft | 3β,7β,15α-Trihydroxy-5-androsten-17-one, its 3,15-dipivalate, and their preparation |
CN1694894A (en) * | 2001-11-14 | 2005-11-09 | 森托科尔公司 | Anti-IL-6 antibodies, compositions, methods and uses |
CN1694897A (en) * | 2002-11-06 | 2005-11-09 | 法玛西亚普强责任有限公司 | Processes for preparing 7-carboxy substituted steroids |
WO2009149392A1 (en) * | 2008-06-06 | 2009-12-10 | Hollis-Eden Pharmaceuticals, Inc. | Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds |
CN105246486A (en) * | 2013-03-13 | 2016-01-13 | 萨奇治疗股份有限公司 | Neuroactive steroids and methods of use thereof |
CN112375115A (en) * | 2013-03-13 | 2021-02-19 | 萨奇治疗股份有限公司 | Neuroactive steroids and methods of use thereof |
CN111410678A (en) * | 2019-01-08 | 2020-07-14 | 成都康弘药业集团股份有限公司 | Steroid compound, use and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114478672B (en) | 2024-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112125805B (en) | Water-soluble magnolol derivative, preparation method of honokiol derivative and intermediate thereof, and related monohydroxy protected intermediate | |
CN113651866A (en) | Novel method for synthesizing cholesterol by taking 21-hydroxy-20-methyl pregn-4-ene-3-one as raw material | |
CN103601782A (en) | Preparation method of prednisone acetate or analogues thereof | |
CN109096122B (en) | Process for preparing spermidine | |
AU2003220251A1 (en) | C-17 spirolactonization and 6,7 oxidation of steroids | |
CN101318986B (en) | Method for synthesizing eplerenone | |
CN114478672B (en) | Synthesis method of HE3286 | |
CN107298694A (en) | The synthetic method and its intermediate of shellfish cholic acid difficult to understand | |
CN112939814B (en) | Preparation method of deuterated dacarbazine intermediate | |
CN114717280A (en) | Synthesis method of monopilavir | |
CN110903259B (en) | Process for efficiently synthesizing Cetilistat by taking 2-amino-5-methylbenzoic acid as raw material | |
CN111018928B (en) | Synthetic method and application of gastrodin hemihydrate | |
CN107383137A (en) | A kind of synthetic method of chenodeoxycholic acid | |
CN113024375A (en) | Preparation method of trans, trans-4-alkyl-4' -pentyl-3 (E) ene-bicyclohexane liquid crystal monomer | |
CN111944004A (en) | Preparation method of halometasone | |
CN111675660A (en) | Preparation method for synthesizing palbociclib intermediate and method for synthesizing palbociclib | |
CN112079894B (en) | Preparation method of Levonorgestrel pharmacopoeia impurity V | |
CN114539288B (en) | Preparation method of everolimus | |
CN112321665A (en) | Method for synthesizing 3 alpha, 7 alpha-dihydroxy-5-beta-cholanic acid from duck cholic acid | |
CN115894303B (en) | Preparation method of (3-amino bicyclo [1.1.1] pentane-1-yl) carbamic acid tert-butyl ester and intermediate thereof | |
JP7344983B2 (en) | Method for preparing chenodeoxycholic acid derivatives | |
CN107417757B (en) | Synthetic method of ursodeoxycholic acid | |
CN108239134B (en) | Obeticholic acid intermediate and preparation method and application thereof | |
CN103443095A (en) | Method for preparing zidovudine and intermediate thereof | |
CN117603167A (en) | Preparation method of high-purity D-ribonic lactone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |